Sat.Aug 24, 2024 - Fri.Aug 30, 2024

article thumbnail

The Truth About AI and Healthcare Payer Modernization

MedCity News

With so much hinging on technology that is the subject of so much hype, it is important to understand where AI actually helps at present — and where it most definitely does not. The post The Truth About AI and Healthcare Payer Modernization appeared first on MedCity News.

article thumbnail

Eli Lilly rolls out direct patient access to weight loss star Zepbound—at a deep discount

Fierce Pharma

Eli Lilly has come up with a new way of supplying its popular weight-loss drug Zepbound that the company hopes could expand access while addressing other issues such as high prices and off-label co | Eli Lilly is offering its popular weight-loss drug Zepbound directly to consumers at a discount through its own online pharmacy. The company hopes the move could expand access while addressing other issues such as high prices and off-label cosmetic usage.

Patients 343
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

AI's Role in Unveiling the True Value of Health Data

Pharma IQ

Understand the potential of AI to unlock the comprehensive value of health data and transform the healthcare sector.

article thumbnail

After an FDA rejection, here’s what’s next in the psychedelics pipeline

PharmaVoice

By rejecting the first MDMA therapy earlier this month, the FDA signaled to the psychedelic drug sector that the road to approval isn’t clear cut.

FDA 134
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Which Clinical Documentation AI Tools Are Health Systems Using?

MedCity News

Health systems across the country are launching enterprise-wide deployments of AI-powered clinical documentation tools. Hospital leaders agree that this technology reduces physician burnout, as well as allows physicians to have more meaningful and productive interactions with patients. The post Which Clinical Documentation AI Tools Are Health Systems Using?

article thumbnail

SCOTUS overturn of Chevron doctrine opens a Pandora's box for biopharma industry, expert says

Fierce Pharma

For the last 40 years, when federal legislation was ambiguous or left an administrative gap, courts were required to defer to the interpretation of federal agencies. | In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services.

Biopharma 310

More Trending

article thumbnail

As pharma’s AI revolution gets underway, ‘hallucinations’ pose a great risk

PharmaVoice

While AI, machine learning and large language models can distill huge amounts of information, they sometimes make mistakes. New technologies could rebuild that trust.

106
106
article thumbnail

The Surprising Rivalries-Turned-Friendships That Are Shaping Diabetes Technology

MedCity News

Over the past decade, Abbott and Dexcom — the two largest makers of continuous glucose monitors — have been teaming up with medical device companies that sell automated insulin delivery systems. Industry experts think these partnerships are smart moves to stay relevant in the rapidly-developing diabetes care space. The post The Surprising Rivalries-Turned-Friendships That Are Shaping Diabetes Technology appeared first on MedCity News.

Medical 117
article thumbnail

Novo rekindles heart failure hopes for semaglutide with new pooled analysis

Fierce Pharma

After a regulatory hiccup earlier this month, Novo Nordisk’s heart failure ambitions for its obesity star Wegovy (semaglutide) are starting to get back on track. | Novo’s semaglutide cut the risk of combined cardiovascular death or worsening heart failure events by 31%, based on an incident rate of 5.4% in semaglutide patients versus 7.5% in those on placebo, the company said Friday.

Patients 276
article thumbnail

European Commission Approves Merck Treatment Combined with Other Therapies for Pulmonary Arterial Hypertension

PharmaTech

In a 24-week study of patients with PAH, six-minute walking distance improved by an average of 40.8 meters, and risk of death or clinical worsening was reduced by 82%.

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

HDA 2024 Traceability Seminar: DSCSA Implementation and Readiness

Pharmaceutical Commerce

Session uncovers distributors’ experiences with the Waiver, Exception, or Exemption request process, and how these affect the overall supply chain.

104
104
article thumbnail

Overcoming the Challenges of Integrating AI in Care Management 

MedCity News

Providers should carefully evaluate how different AI models can be strategically integrated to optimize the care management lifecycle and address the complex needs of their patients and populations, while at the same time prioritizing patient safety and ethical considerations. The post Overcoming the Challenges of Integrating AI in Care Management appeared first on MedCity News.

article thumbnail

AbbVie's Ubrelvy wards off migraines when used in reaction to early warning signs: study

Fierce Pharma

Despite competing against several drugs that have been approved to fend off migraine headaches, AbbVie’s Ubrelvy (ubrogepant) —which is approved only to treat them—has carved out a significant nich | Recent trial results indicate that AbbVie's migraine treatment Ubrelvy works as a preventative. In a study published this week in the journal Neurology, Ubrelvy was 73% more effective in preventing a migraine attack than placebo.

296
296
article thumbnail

Pfizer joins Lilly in direct-to-consumer drive

pharmaphorum

Pfizer has become the latest big pharma group to launch a web-based platform that opens up a direct-to-consumer channel for medicines access.This morning, the company announced the launch in the US of PfizerForAll, a digital platform that it says provides access to same-day appointments with healthcare professionals – in-person or via a $35 telehealth visit – along with home delivery of medicines and diagnostics, vaccination appointments, and payment support.

Medicine 114
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

FDA Grants Orphan Drug Designation to RedHill’s Treatment for Neuroblastoma

PharmaTech

Opaganib was given orphan drug designation for the treatment of neuroblastoma in children, which is rare, but the most common infancy malignancy.

FDA 98
article thumbnail

Why Pfizer Is Dipping Into DTC Telehealth With PfizerForAll

MedCity News

To address the complicated healthcare landscape in the U.S., Pfizer launched a new direct-to-consumer virtual service called PfizerForAll. It follows Eli Lilly, which launched a similar product in January. The post Why Pfizer Is Dipping Into DTC Telehealth With PfizerForAll appeared first on MedCity News.

article thumbnail

Merck’s Keytruda flunks pivotal studies in early-stage lung and skin cancers

Fierce Pharma

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer. | A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

320
320
article thumbnail

Roche gets EU nod for subcutaneous PNH drug PiaSky

pharmaphorum

Roche's PiaSky is the first therapy for rare blood disorder PNH that can be given by monthly subcutaneous injection in the EU.

113
113
article thumbnail

How to Stay Competitive in the Evolving State of Martech

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

article thumbnail

Are PBMs to blame for high drug prices in the US?

Pharmaceutical Technology

US Congress labelled pharmacy benefit managers (PBMs) as ‘anticompetitive’; PBMs blame manufacturers for increasing pharmaceutical prices.

article thumbnail

Building an Effective Denial Prevention Team to Mitigate Revenue Loss

MedCity News

Sluggish margins and high costs have created a challenging environment for provider organizations. With the number of denied claims increasing significantly over the past few years, so has the time and resources needed to manage those denials. The post Building an Effective Denial Prevention Team to Mitigate Revenue Loss appeared first on MedCity News.

article thumbnail

BioMarin cuts deeper with 225 layoffs under CEO's new corporate strategy

Fierce Pharma

The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech. | The rightsizing at BioMarin continues to take its toll as CEO Alexander Hardy devises a new corporate strategy for the rare disease biotech.

320
320
article thumbnail

Details emerge of £400m investment programme tied to VPAG

pharmaphorum

The £400m pledged by industry as part of the new VPAG voluntary scheme of pharma rebates will be used mainly to support the UK clinical research sector

Pharma 116
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A

article thumbnail

HDA 2024 Traceability Seminar: A Legal Perspective Regarding DSCSA

Pharmaceutical Commerce

Panel offers suggestions on how compliance teams should be considering handling SOPs, stabilization, and much more.

101
101
article thumbnail

Healthcare Needs to Be Proactive, Not Reactive — How Patient Education Improves Outcomes

MedCity News

Educational materials that are relatable and personalized can increase engagement. Here’s what is needed to create educational materials that empower patients and lead to better outcomes. The post Healthcare Needs to Be Proactive, Not Reactive — How Patient Education Improves Outcomes appeared first on MedCity News.

Education 111
article thumbnail

Emergent's smallpox vaccine picks up FDA nod for mpox as Africa outbreak spreads

Fierce Pharma

As a new deadly strain of mpox continues its global spread, Emergent BioSoultion's smallpox vaccine ACAM2000 has officially joined the ranks of FDA-approved defense measures against the virus. | With the nod, Emergent's vaccine joins Bavarian Nordic's Jynneos as approved protection options to address the continued outbreak in Africa, which was recently deemed a public health emergency.

FDA 304
article thumbnail

Neurocrine slides as schizophrenia data disappoints

pharmaphorum

Shares in Neurocrine Biosciences took a tumble after it reported mid-stage data for a key pipeline drug for schizophrenia that failed to impress investors

104
104
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Singapore approves mpox vaccine as it adds border infection checks

Pharmaceutical Technology

Unlike its close neighbour Thailand, Singapore has not yet confirmed an mpox clade Ib case.

111
111
article thumbnail

A Revolution in Military Medical Staffing is Afoot and Private Sector Firms are Playing a Big Part

MedCity News

No revolutionary naval vessels, fighter planes, or weapon systems were involved. Rather, this one was about staffing military healthcare facilities. Make no mistake, though: It’s also revolutionary. The post A Revolution in Military Medical Staffing is Afoot and Private Sector Firms are Playing a Big Part appeared first on MedCity News.

Medical 107
article thumbnail

UCB sells off production plant and a clutch of older meds in China for $680M

Fierce Pharma

Restructuring seems to be the name of the game for many large drugmakers these days, and Belgium-based UCB is no except | Belgium’s UCB is selling off its mature neurology and allergy business—plus a manufacturing plant—in mainland China. The deal will see local healthcare asset manager CBC Group and Abu Dhabi-based investment firm Mubadala pay UCB $680 million.

article thumbnail

Women's health DTx developer Curio raises funds for PPD app

pharmaphorum

Digital health firm Curio raises $10m+ in first-round financing that will be used to fund the rollout of its MamaLift Plus app for postpartum depression

104
104
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.